First Financial Equity Corporation’s Regulus Therapeutics RGLS Stock Holding History

First Financial Equity Corporation’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$22K	Buy	+116	New	+$22.1K	﹤0.01%	443

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Financial Equity Corporation's RGLS Position: Q1 2017 in Review

First Financial Equity Corporation opened a new position in Regulus Therapeutics (RGLS) in Q1 2017: 116 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #443 among its holdings.

58 funds tracked by Wall St. Rank hold RGLS as of Q1 2017.

First Financial Equity Corporation held 116 shares of Regulus Therapeutics worth $22K as of Q1 2017.
Regulus Therapeutics was a new First Financial Equity Corporation position in Q1 2017.
Regulus Therapeutics made up ﹤0.01% of First Financial Equity Corporation's portfolio in Q1 2017, its #443 holding.
58 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2017.

Based on First Financial Equity Corporation's 13F filing for Q1 2017, filed 16 May 2017.